Perinatal Stem Cells. Research and Therapy

Table of Contents

Section I. Amniotic Fluid-Derived Stem Cells

1. In utero therapy for congenital disorders using amniotic fluid stem cells

2. The Amniotic Fluid Stem Cell Secretome: at the Heart of Regeneration

3. Transplantation of Amniotic Fluid-Derived Neural Stem Cells

4. Stroke therapy: the potential of amniotic fluid-derived stem cells

5. Vascular formation by human perinatal stem cells

6. Amniotic Fluid Stem Cells for Kidney Regeneration

Section II. Placental and Placental Membrane-Derived Stem Cells

7. Placental mesenchymal stem cells for cellular cardiomyoplasty

8. Heterogeneous functions of perinatal mesenchymal stromal cells require a preselection before their banking for clinical use

9. Defining the fetal stem cell niche in the human placenta

10. Banking placental tissue hematopoietic stem cells and mesenchymal stem cells for clinical use

11. Immuno-modulatory mechanisms of placental stem cells

12. Amnion Membrane Allograft for Regenerative Medicine

13. Perinatal cells and biomaterials for wound healing

14. Placental Stem Cells

15. Therapeutic Effect of Extracellular Vesicles Derived from Adult/Perinatal Human Mesenchymal Stem Cells

Section III. Umbilical Cord-Derived Cells

16. Ex-vivo Expansion of Cord Blood Stem Cells

17. Cord Blood Transplantation: Therapeutic Use of Perinatal Stem Cells

18. Autologous Human Cord Blood as a Treatment for Traumatic Brain Injury in Children

19. Phenotypic and Functional Characterization Perinatal Stem Cells Isolated from Umbilical Cord Tissue

20. Mesenchymal stromal cells from Wharton's jelly (WJ-MSCs): coupling their hidden differentiative program with their frank immunomodulatory phenotype

21. Regeneration of ischemic cardiovascular damage using Jelly Wharton as an unlimited source of therapeutic stem cells

22. Phenotype with Focused Paracrine Fractions: Effecting Future Phenotype with Focused Paracrine Fractions

Section IV. Clinical and Industry Perspective

23. Clinical Translation of Perinatal Stem Cell Therapy

24. Current Clinical Trials utilizing Perinatal Stem Cells
A Review

25. Review Of Processing Technology and Techniques for Perinatal Stem Cells Banking And Clinical Applications

26. Clinical Development And Commercialization Of Placenta-Derived Cell Therapy

27. How the patent landscape has changed

28. The Need for Better Assays to Predict the Effectiveness of Tissue Stem Cell Treatments

Authors

Anthony Atala Department of Urology, Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA. Anthony Atala is the Director of the Wake Forest Institute for Regenerative Medicine, and the W.H. Boyce Professor and Chair of the Department of Urology at Wake Forest University. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. His current work focuses on growing new human cells, tissues and organs. Dr. Atala works with several journals and serves in various roles, including Editor-in-Chief of Stem Cells- Translational Medicine, Current Stem Cell Research and Therapy, and Therapeutic Advances in Urology; as Associate Editor of Tissue Engineering and Regenerative Medicine, Rejuvenation Research, and Gene Therapy and Regulation; as Executive Board Member or Section Editor of the International Journal of Artificial Organs, Organogenesis, and Current Urology Reports; and as Editorial Board member of Expert Opinion on Biological Therapy, Biomedical Materials, Journal of Tissue Science and Engineering, 3D Printing and Additive Manufacturing, Technology, the Journal of Urology, Recent Patents on Regenerative Medicine, BioMed Central-Urology, Urology, and Current Transplantation Reports. Dr. Atala is a recipient of many awards, including the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society, the World Technology Award in Health and Medicine, presented to individuals achieving significant and lasting progress, the Samuel D. Gross Prize, awarded every 5 years to a national leading surgical researcher by the Philadelphia Academy of Surgery, the Barringer Medal from the American Association of Genitourinary Surgeons for distinguished accomplishments, the Gold Cystoscope award from the American Urological Association for advances in the field, the Ramon Guiteras Award for pioneering research in regenerative medicine and outstanding contributions as a scholar and teacher, the Innovation Award from the Society of Manufacturing Engineers for the creation of synthetic organs, and the Rocovich Gold Medal, awarded to a distinguished scientist who has made a major impact on science toward the understanding of human disease. In 2011 he was elected to the Institute of Medicine of the National Academy of Sciences. Kyle J. Cetrulo Chief Executive Officer, AuxoCell Laboratories, Inc., Cambridge, MA, USA. Rouzbeh R. Taghizadeh Co-Founder, Chief Scientific Officer, AuxoCell Laboratories, Inc., Cambridge, MA, USA. Curtis L Cetrulo Assistant Professor, Surgery, Harvard Medical School, Plastic and Reconstructive Surgery, Surgery, Massachusetts General Hospital, USA. Sean Murphy Assistant Professor, Wake Forest Institute for Regenerative Medicine, USA.